Intelligence / Healthtech / New Clinical Trials / Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd.
Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd.
22 Oct 2026: Trial registered · A Phase II Study of FXR0906 in Patients With Severe Hypertriglyceridemia or Hypertriglyceridemia With ASCVD.. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 22 Oct 2026
- Title
- A Phase II Study of FXR0906 in Patients With Severe Hypertriglyceridemia or Hypertriglyceridemia With ASCVD.
- Conditions
- sHTG, HTG With ASCVD (Diagnosed or at Increased Risk)
- Phase
- Phase 2
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- China
- Country
- China
- Reference
- NCT07889245
- Location
- China
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from China
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.